Biomarkers in screening of cervical cancer

Emerging Issues on HPV Infections: From Science to Practice

Volumn , Issue , 2006, Pages 1-19

  von Knebel Doeberitz, Magnus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547118671     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000092732     Document Type: Chapter

References (82)

1. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Arch Pathol Lab Med 1997;121:211-224.
2. Anderson CM, Thornton JG. Screening for cervical cancer. Graphs may mislead. BMJ 1994;309: 953-954.
3. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001;285:1500-1505.
4. Solomon D. Chapter 14: role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr 2003;31:97-101.
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
6. Syrjänen K, Syrjänen S. Epidemiology of human papilloma virus infections and genital neoplasia. Scand J Infect Dis Suppl 1990;69:7-17.
7. Zur Hausen H. Disrupted dichotomous intracellular control of human papillomavirus infection in cancer of the cervix. Lancet 1994;343:955-957.
8. Mantovani F, Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001;20:7874-7887.
9. Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL, Grace M, et al. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 2001;20:7888-7898.
10. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004;109:157-162.
11. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993;12:186-192.
12. Solomon D, Nayar R. The Bethesda System for Reporting Cervical Cytology. Definitions, Criteria, and Explanatory Notes. New York, Springer, 2004.
13. Duensing S, Lee LY, Duensing A, Basile J, Piboonniyom S, Gonzalez S, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci USA 2000;97:10002-10007.
14. Allen DG, White DJ, Hutchins AM, Scurry JP, Tabrizi SN, Garland SM, et al. Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer. Br J Cancer 2000;83:1659-1663.
15. Heselmeyer K, Macville M, Schrock E, Blegen H, Hellstrom AC, Shah K, et al. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 1997;19:233-240.
16. Kirchhoff M, Rose H, Petersen BL, Maahr J, Gerdes T, Lundsteen C, et al. Comparative genomic hybridization reveals a recurrent pattern of chromosomal aberrations in severe dysplasia/carcinoma in situ of the cervix and in advanced-stage cervical carcinoma. Genes Chromosomes Cancer 1999;24:144-150.
17. Matthews CP, Shera KA, McDougall JK. Genomic changes and HPV type in cervical carcinoma. Proc Soc Exp Biol Med 2000;223:316-321.
18. Wentzensen N, Vinokurova S, von Knebel DM. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res 2004;64:3878-3884.
19. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 1995;69:2989-2997.
20. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 1995;92:1654-1658.
21. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, et al. Detection of highrisk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999;59:6132-6136.
22. Hopman AH, Kamps MA, Smedts F, Speel EJ, Herrington CS, Ramaekers FC. HPV in situ hybridization: impact of different protocols on the detection of integrated HPV. Int J Cancer 2005;96:345-353.
23. Luft F, Klaes R, Nees M, Durst M, Heilmann V, Melsheimer P, et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int J Cancer 2001;92:9-17.
24. Ziegert C, Wentzensen N, Vinokurova S, Kisseljov F, Einenkel J, Hoeckel M, et al. A comprehensive analysis of HPV integration loci in anogenital lesions combining transcript and genome-based amplification techniques. Oncogene 2003;22:3977-3984.
25. Vinokurova S, Wentzensen N, Einenkel J, Klaes R, Ziegert C, Melsheimer P, et al. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst 2005;97:1816-1821.
26. Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel DM. DNA aneuploidy and integration of human papillomavirus type 16 E6/E7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res 2004;10:3059-3063.
27. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168-174.
28. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 2002;21:5400-5413.
29. Dong SM, Kim HS, Rha SH, Sidransky D. Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 2001;7:1982-1986.
30. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M, Gazdar AF. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001;7:584-589.
31. Steenbergen RDM, Kramer D, Braakhuis BJM, Stern PL, Verheijen RHM, Meijer CJLM, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004;96:294-305.
32. Feng Q, Balasubramanian A, Hawes SE, Toure P, Sow PS, Dem A, et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005;97:273-282.
33. Chen Y, Miller C, Mosher R, Zhao X, Deeds J, Morrissey M, et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res 2003;63:1927-1935.
34. Sopov I, Sorensen T, Magbagbeolu M, Jansen L, Beer K, Kuhne-Heid R, et al. Detection of cancer-related gene expression profiles in severe cervical neoplasia. Int J Cancer 2004;112:33-43.
35. Santin AD, Zhan F, Bignotti E, Siegel ER, Cane S, Bellone S, et al. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology 2005;331:269-291.
36. Keating JT, Ince T, Crum CP. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001;8:83-92.
37. Williams GH, Romanowski P, Morris L, Madine M, Mills AD, Stoeber K, et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci USA 1998;95:14932-14937.
38. El Ghobashy AA, Shaaban AM, Herod J, Innes J, Prime W, Herrington CS. Overexpression of cyclins A and B as markers of neoplastic glandular lesions of the cervix. Gynecol Oncol 2004;92: 628-634.
39. Quade BJ, Park JJ, Crum CP, Sun D, Dutta A. In vivo cyclin E expression as a marker for early cervical neoplasia. Mod Pathol 1998;11:1238-1246.
40. Weaver EJ, Kovatich AJ, Bibbo M. Cyclin E expression and early cervical neoplasia in ThinPrep specimens. A feasibility study. Acta Cytol 2000;44:301-304.
41. Liao SY, Brewer C, Zavada J, Pastorek J, Pastorekova S, Manetta A, et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 1994;145:598-609.
42. Lieskovska J, Opavsky R, Zacikova L, Glasova M, Pastorek J, Pastorekova S. Study of in vitro conditions modulating expression of MN/CA IX protein in human cell lines derived from cervical carcinoma. Neoplasma 1999;46:17-24.
43. Liao SY, Stanbridge EJ. Expression of the MN antigen in cervical Papanicolaou smears is an early diagnostic biomarker of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 1996;5:549-557.
44. Liao SY, Stanbridge EJ. Expression of MN/CA9 protein in Papanicolaou smears containing atypical glandular cells of undetermined significance is a diagnostic biomarker of cervical dysplasia and neoplasia. Cancer 2000;88:1108-1121.
45. von Knebel Doberitz M, Oltersdorf T, Schwarz E, Gissmann L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988;48:3780-3786.
46. von Knebel Doberitz M, Gissmann L, Zur Hausen H. Growth-regulating functions of human papillomavirus early gene products in cervical cancer cells acting dominant over enhanced epidermal growth factor receptor expression. Cancer Res 1990;50:3730-3736.
47. von Knebel Doberitz M, Rittmuller C, Zur Hausen H, Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 1992;51: 831-834.
48. von Knebel Doberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-2242.
49. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996;93:4350-4354.
50. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003;22:4212-4222.
51. Sherr CJ. Principles of tumor suppression. Cell 2004;116:235-246.
52. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003;532:39-49.
53. Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K, Wada H, et al. Alteration of p16 and p15 genes in human uterine tumours. Br J Cancer 1999;80:458-467.
54. Yang HJ, Liu VW, Wang Y, Chan KY, Tsang PC, Khoo US, et al. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 2004;93:435-440.
55. Kim JW, Namkoong SE, Ryu SW, Kim HS, Shin JW, Lee JM, et al. Absence of p15INK4B and p16INK4A gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection. Gynecol Oncol 1998;70:75-79.
56. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-284.
57. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int 1998;48:580-585.
58. Ansari-Lari MA, Staebler A, Zaino RJ, Shah KV, Ronnett BM. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 2004;28:160-167.
59. Cameron RI, Maxwell P, Jenkins D, McCluggage WG. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tuboendometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology 2002;41: 313-321.
60. McCluggage WG, Jenkins D. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 2003;22:231-235.
61. McCluggage WG. Re: distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papilloma virus (HPV) DNA detection. Am J Surg Pathol 2004;28:974.
62. Negri G, Egarter-Vigl E, Kasal A, Romano F, Haitel A, Mian C. p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003;27:187-193.
63. Riethdorf L, Riethdorf S, Lee KR, Cviko A, Loning T, Crum CP. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia. Hum Pathol 2002;33:899-904.
64. Tringler B, Gup CJ, Singh M, Groshong S, Shroyer AL, Heinz DE, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004;35: 689-696.
65. Negri G, Vittadello F, Romano F, Kasal A, Rivasi F, Girlando S, et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 2004;445:616-620.
66. Wang JL, Zheng BY, Li XD, Angstrom T, Lindstrom MS, Wallin KL. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 2004;10:2407-2414.
67. Wang SS, Trunk M, Schiffman M, Herrero R, Sherman ME, Burk RD, et al. Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a populationbased cohort in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13:1355-1360.
68. Trunk MJ, Dallenbach-Hellweg G, Ridder R, Petry KU, Ikenberg H, Schneider V, et al. Morphologic characteristics of p16INK4a-positive cells in cervical cytology samples. Acta Cytol 2004;48:771-782.
69. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1389-1399.
70. Akpolat I, Smith DA, Ramzy I, Chirala M, Mody DR. The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material. Cancer 2004;102:142-149.
71. Bibbo M, Klump WJ, DeCecco J, Kovatich AJ. Procedure for immunocytochemical detection of p16INK4A antigen in thin-layer, liquid-based specimens. Acta Cytol 2002;46:25-29.
72. Bibbo M, DeCecco J, Kovatich AJ. p16INK4A as an adjunct test in liquid-based cytology. Anal Quant Cytol Histol 2003;25:8-11.
73. Murphy N, Ring M, Killalea AG, Uhlmann V, O'Donovan M, Mulcahy F, et al. p16INK4A as a marker for cervical dyskaryosis: CIN and cGIN in cervical biopsies and ThinPrep smears. J Clin Pathol 2003;56:56-63.
74. Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of p16INK4A in Papanicolaou smears containing atypical squamous cells of undetermined significance from the uterine cervix. Gynecol Oncol 2003;91:201-208.
75. Nieh S, Chen SF, Chu TY, Lai HC, Fu E. Expression of p16INK4A in Pap smears containing atypical glandular cells from the uterine cervix. Acta Cytol 2004;48:173-180.
76. Pientong C, Ekalaksananan T, Swadpanich U, Kongyingyoes B, Kritpetcharat O, Yuenyao P, et al. Immunocytochemical detection of p16INK4a protein in scraped cervical cells. Acta Cytol 2003;47:616-623.
77. Pientong C, Ekalaksananan T, Kongyingyoes B, Kritpetcharat O, Swadpanich U, Pengsa P, et al. Immunocytochemical staining of p16INK4a protein from conventional Pap test and its association with human papillomavirus infection. Diagn Cytopathol 2004;31:235-242.
78. Sahebali S, Depuydt CE, Segers K, Moeneclaey LM, Vereecken AJ, Van Marck E, et al. p16INK4a as an adjunct marker in liquid-based cervical cytology. Int J Cancer 2004;108:871-876.
79. Saqi A, Pasha TL, McGrath CM, Yu GH, Zhang P, Gupta P. Overexpression of p16INK4A in liquidbased specimens (SurePath) as marker of cervical dysplasia and neoplasia. Diagn Cytopathol 2002;27:365-370.
80. Yoshida T, Fukuda T, Sano T, Kanuma T, Owada N, Nakajima T. Usefulness of liquid-based cytology specimens for the immunocytochemical study of p16 expression and human papillomavirus testing: a comparative study using simultaneously sampled histology materials. Cancer 2004;102:100-108.
81. Guo M, Hu L, Baliga M, He Z, Hughson MD. The predictive value of p16(INK4a) and hybrid capture human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2004;122:894-901.
82. INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 2005;105:461-467.